Fang Shenzhe, Wang Xinxue, Wu Xiang, Li Hong
Department of Hepatopancreatobiliary Surgery, The Affiliated Lihuili Hospital, Ningbo University, Ningbo, China.
J Gastrointest Oncol. 2023 Feb 28;14(1):405-419. doi: 10.21037/jgo-22-1292. Epub 2023 Feb 21.
Adenosquamous carcinoma of the gallbladder (GBASC) is a rare histological variant without defined appropriate clinical measures.
Using the Surveillance, Epidemiology, and End Results (SEER) database, data on a cohort of patients with GBASC were collected from 21 cancer registries between 1975 and 2018. We used Kaplan-Meier analysis to evaluate the effectiveness of different treatment regimens on patients with GBASC. Then we used Cox proportional hazards regression method to determine the prognostic factors for cancer-specific survival (CSS) of GBASC patients.
A total of 388 patients with GBASC were identified: 80 patients diagnosed as early stage and 308 patients diagnosed as advanced stage. For early-stage GBASC, radical lymph node dissection improved the CSS significantly; for advanced-stage GBASC, radical surgery, nonradical surgery, lymph node dissection, chemotherapy, and radiotherapy improved the CSS significantly. Surgery, lymph node dissection, radiation, chemotherapy, age, race, and the American Joint Committee on Cancer (AJCC) stage were the independent risk factors for the CSS of GBASC patients.
Radical intraoperative lymph node dissection provided a survival benefit for patients with early-stage GBASC, whereas chemotherapy and radiotherapy provided no significant benefit; surgical treatment, more complete lymph node dissection, radiotherapy, and chemotherapy provided survival benefits for patients with advanced GBASC. The prognosis for GBASC patients is affected by the factors of surgery, lymph node dissection, radiation, chemotherapy, age, race, and the AJCC stage.
胆囊腺鳞癌(GBASC)是一种罕见的组织学变异类型,尚无明确的合适临床治疗措施。
利用监测、流行病学和最终结果(SEER)数据库,收集了1975年至2018年间21个癌症登记处的GBASC患者队列数据。我们采用Kaplan-Meier分析来评估不同治疗方案对GBASC患者的疗效。然后我们使用Cox比例风险回归方法来确定GBASC患者癌症特异性生存(CSS)的预后因素。
共识别出388例GBASC患者:80例诊断为早期,308例诊断为晚期。对于早期GBASC,根治性淋巴结清扫显著改善了CSS;对于晚期GBASC,根治性手术、非根治性手术、淋巴结清扫、化疗和放疗显著改善了CSS。手术、淋巴结清扫、放疗、化疗、年龄、种族和美国癌症联合委员会(AJCC)分期是GBASC患者CSS的独立危险因素。
术中根治性淋巴结清扫为早期GBASC患者带来生存获益,而化疗和放疗未带来显著获益;手术治疗、更彻底的淋巴结清扫、放疗和化疗为晚期GBASC患者带来生存获益。GBASC患者的预后受手术、淋巴结清扫、放疗、化疗、年龄、种族和AJCC分期等因素影响。